We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Clinical Significance of Tumor Markers for Advanced Thymic Carcinoma: A Retrospective Analysis from the NEJ023 Study.
- Authors
Mimori, Tomoyasu; Shukuya, Takehito; Ko, Ryo; Okuma, Yusuke; Koizumi, Tomonobu; Imai, Hisao; Takiguchi, Yuichi; Miyauchi, Eisaku; Kagamu, Hiroshi; Sugiyama, Tomohide; Azuma, Keisuke; Namba, Yukiko; Yamasaki, Masahiro; Tanaka, Hisashi; Takashima, Yuta; Soda, Sayo; Ishimoto, Osamu; Koyama, Nobuyuki; Kobayashi, Kunihiko; Takahashi, Kazuhisa
- Abstract
Simple Summary: Advanced thymic carcinoma (ATC) is rare. Owing to its rarity, there is limited information on the prognostic factors, and the optimal serum tumor markers are also unknown. We conducted a multi-institutional retrospective study of patients with ATC. In this study, we collected data on patient characteristics, progression-free survival (PFS), overall survival (OS), and tumor marker values, and investigated the relationship between tumor marker values and PFS/OS. We found that the neuron-specific enolase (NSE) level may be a useful prognostic tumor marker for ATC, regardless of histology. The findings of the analysis limited to squamous cell carcinoma suggested that the NSE and squamous cell carcinoma antigen levels may be useful prognostic factors. The optimal tumor marker for predicting the prognosis of advanced thymic carcinoma (ATC) remains unclear. We conducted a multi-institutional retrospective study of patients with ATC. A total of 286 patients were treated with chemotherapy. Clinicopathological information, including serum tumor markers, was evaluated to determine the overall survival (OS) and progression-free survival (PFS). The carcinoembryonic antigen, cytokeratin-19 fragment, squamous cell carcinoma (SCC) antigen, progastrin-releasing peptide, neuron-specific enolase (NSE), and alpha-fetoprotein levels were evaluated. In the Kaplan–Meier analysis, the OS was significantly shorter in the patients with elevated NSE levels than in those with normal NSE levels (median, 20.3 vs. 36.8 months; log-rank test p = 0.029; hazard ratio (HR), 1.55; 95% confidence interval (CI), 1.05–2.31 (Cox proportional hazard model)); a similar tendency regarding the PFS was observed (median, 6.4 vs. 11.0 months; log-rank test p = 0.001; HR, 2.04; 95% CI, 1.31–3.18). No significant differences in the OS and PFS were observed among the other tumor markers. In both univariate and multivariate analyses of the patients with SCC only, the NSE level was associated with the OS and PFS. Thus, the NSE level may be a prognostic tumor marker for thymic carcinoma, regardless of histology.
- Subjects
STATISTICS; THYMUS tumors; CONFIDENCE intervals; CANCER chemotherapy; MULTIVARIATE analysis; RETROSPECTIVE studies; KAPLAN-Meier estimator; DESCRIPTIVE statistics; TUMOR markers; ANTIGENS; PROPORTIONAL hazards models
- Publication
Cancers, 2022, Vol 14, Issue 2, p331
- ISSN
2072-6694
- Publication type
Article
- DOI
10.3390/cancers14020331